Edition:
United Kingdom

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

7.74EUR
4:35pm GMT
Change (% chg)

€-0.19 (-2.40%)
Prev Close
€7.93
Open
€7.81
Day's High
€7.95
Day's Low
€7.66
Volume
366,257
Avg. Vol
344,356
52-wk High
€9.44
52-wk Low
€4.41

Chart for

About

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of... (more)

Overall

Beta: 1.11
Market Cap(Mil.): €603.39
Shares Outstanding(Mil.): 57.36
Dividend: --
Yield (%): --

Financials

  IPH.PA Industry Sector
P/E (TTM): -- 69.71 34.39
EPS (TTM): -0.14 -- --
ROI: -4.04 9.01 14.96
ROE: -10.93 10.15 16.52

BRIEF-Innate Pharma Announces Updated Results On IPH4102

* ANNOUNCED ON MONDAY UPDATED RESULTS THAT SUPPORT ADVANCEMENT OF IPH4102 IN REFRACTORY SÉZARY SYNDROME

04 Dec 2018

AstraZeneca digs deeper into cancer with Innate stake

LONDON/PARIS AstraZeneca is ploughing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma , which includes the British group buying a 9.8 percent stake in the French biotech company.

23 Oct 2018

AstraZeneca digs deeper into cancer with Innate stake

LONDON/PARIS AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company.

23 Oct 2018

UPDATE 2-AstraZeneca digs deeper into cancer with Innate stake

* Innate shares jump 29 percent (Updates with executive interviews, latest shares)

23 Oct 2018

French and Benelux stocks-Factors to watch on Oct 23

Oct 23 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.

23 Oct 2018

AstraZeneca to buy 9.8 pct stake in France's Innate Pharma

PARIS, Oct 23 British drugmaker AstraZeneca will buy a newly-issued equity stake of 9.8 percent in smaller French peer Innate Pharma, strengthening its presence in the field of immuno-oncology.

23 Oct 2018

BRIEF-Innate Pharma: Phase II Results From Monalizumab/Cetuximab In Head And Neck Cancer

* INNATE PHARMA ANNOUNCED ON SATURDAY PHASE II RESULTS FROM MONALIZUMAB/CETUXIMAB IN HEAD AND NECK CANCER

22 Oct 2018

BRIEF-Innate Pharma Publishes Phase 1 IPH4102 Results

* REPORTED ON SATURDAY IPH4102 PHASE 1 RESULTS IN ADVANCED CUTEANOUS T CELL LYMPHOMA

01 Oct 2018

Earnings vs. Estimates